Compounds > promestriene
Page last updated: 2024-11-11

promestriene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

promestriene: 3 propyl-ether-17 beta-methyl-ether of ESTRADIOL [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9883915
CHEMBL ID2105394
CHEBI ID135402
SCHEMBL ID5188890
MeSH IDM0061599

Synonyms (37)

Synonym
3-propoxy-17beta-methoxy-1,3,5(10)-estratriene
c22h32o2
promestriene (inn)
39219-28-8
colpotrophine (tn)
D07221
CHEBI:135402
promestriene
colpotrophine
CHEMBL2105394
S3657
17beta-methoxy-3-propoxyestra-1,3,5(10)-triene
promestriene [inn:dcf]
gxm4per6wz ,
promestriano
einecs 254-361-6
unii-gxm4per6wz
promestriano [inn-spanish]
promestrienum [inn-latin]
AKOS015895176
promestriene [mart.]
promestriene [inn]
promestriene [who-dd]
SCHEMBL5188890
3-propyl ethyl
17b-methyl estradiol
(1s,3as,3br,9bs,11as)-1-methoxy-11a-methyl-7-propoxy-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene
AS-69299
C90471
(8r,9s,13s,14s,17s)-17-methoxy-13-methyl-3-propoxy-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthrene
BCP05212
mfcd00867247
HY-108293
estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17b)-
CCG-267796
CS-0028159
3-propoxy-17-methoxyestra-1,3,5(10)-triene

Research Excerpts

Overview

Promestriene is an analogue of oestradiol which is minimally absorbed. It has been shown to be effective in reversing atrophic changes caused by oestrogen deficiency.

ExcerptReferenceRelevance
"Promestriene is an analogue of oestradiol which is minimally absorbed and it has been shown to be effective in reversing atrophic changes caused by oestrogen deficiency in women undergoing natural or surgically induced menopause."( Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy.
Clissold, S; Santos, I, 2010)		1.32

Toxicity

ExcerptReferenceRelevance
" In the mean time, adverse effect was recorded."( [Safety of promestriene capsule used in postmenopausal atrophic vaginitis].
Jing, LH; Lin, SQ; Sun, AJ; Wang, ZY; Ye, JL; Zhang, Y, 2009)		0.74
"(1) SAFETY: during promestriene treatment, no case with adverse effect was observed."( [Safety of promestriene capsule used in postmenopausal atrophic vaginitis].
Jing, LH; Lin, SQ; Sun, AJ; Wang, ZY; Ye, JL; Zhang, Y, 2009)		1.07
"The premestriene capsule was safe and effective in the treatment of postmenopausal atrophic vaginitis."( [Safety of promestriene capsule used in postmenopausal atrophic vaginitis].
Jing, LH; Lin, SQ; Sun, AJ; Wang, ZY; Ye, JL; Zhang, Y, 2009)		0.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (23.53)18.7374
1990's6 (17.65)18.2507
2000's4 (11.76)29.6817
2010's9 (26.47)24.3611
2020's7 (20.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.24 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index82.50 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (52.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (45.71%)5.53%
Reviews3 (8.57%)6.00%
Case Studies3 (8.57%)4.05%
Observational0 (0.00%)0.25%
Other13 (37.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		3.852116alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		8.461117-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		1.971017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
chlorquinaldol
Chlorquinaldol: Local anti-infective agent used for skin, gastrointestinal, and vaginal infections with fungi, protozoa, and certain bacteria. In animals, it causes central nervous system damage and is not administered parenterally. It is also used as antiseptic, fungistat, or deodorant.. chlorquinaldol : A monohydroxyquinoline that is quinolin-8-ol which is substituted by a methyl group at position 2 and by chlorine at positions 5 and 7. An antifungal and antibacterial, it was formerly used for topical treatment of skin conditions and vaginal infections.		4.0731monohydroxyquinoline;
organochlorine compound		antibacterial drug;
antiprotozoal drug;
antiseptic drug
boric acid
[no description available]		1.9810boric acidsastringent
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		8.811heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
estrone sulfate
estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd		8.461117-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
chiniofon
Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Atrophy
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.		09.25117
Symptom Cluster
[description not available]		05.0633
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		010.7673
Syndrome
A characteristic symptom complex.		05.0633
Breast Cancer
[description not available]		08.9911
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.9911
Fistula
Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.		04.5511
Complication, Postoperative
[description not available]		05.4422
Urethral Diseases
Pathological processes involving the URETHRA.		04.5511
Dehiscence, Surgical Wound
[description not available]		04.5511
Hypospadias
A birth defect due to malformation of the URETHRA in which the urethral opening is below its normal location. In the male, the malformed urethra generally opens on the ventral surface of the PENIS or on the PERINEUM. In the female, the malformed urethral opening is in the VAGINA.		16.5511
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		05.4422
Chronic Illness
[description not available]		03.5911
HPV Infection
[description not available]		03.5911
Cervicitis
[description not available]		08.5911
Uterine Cervicitis
Inflammation of the UTERINE CERVIX.		03.5911
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		03.5911
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.		03.5911
Sex Disorders
[description not available]		03.5911
Female Genitourinary Diseases
[description not available]		05.5131
Sexual Dysfunction, Physiological
Physiological disturbances in normal sexual performance in either the male or the female.		03.5911
Benign Neoplasms
[description not available]		0310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		0310
Urogenital Prolapse
[description not available]		03.5111
Pelvic Organ Prolapse
Abnormal descent of a pelvic organ resulting in the protrusion of the organ beyond its normal anatomical confines. Symptoms often include vaginal discomfort, DYSPAREUNIA; URINARY STRESS INCONTINENCE; and FECAL INCONTINENCE.		03.5111
Cervix Dysplasia
[description not available]		03.4311
Cancer of Cervix
[description not available]		03.4311
Uterine Cervical Dysplasia
Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE.		03.4311
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		03.4311
Vaginal Diseases
Pathological processes of the VAGINA.		05.2443
Urinary Incontinence, Stress
Involuntary discharge of URINE as a result of physical activities that increase abdominal pressure on the URINARY BLADDER without detrusor contraction or overdistended bladder. The subtypes are classified by the degree of leakage, descent and opening of the bladder neck and URETHRA without bladder contraction, and sphincter deficiency.		04.3922
Vaginitis
Inflammation of the vagina characterized by pain and a purulent discharge.		04.0631
Female Genital Neoplasms
[description not available]		03.4611
Dyspareunia
Recurrent genital pain occurring during, before, or after SEXUAL INTERCOURSE in either the male or the female.		03.4611
Genital Neoplasms, Female
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).		03.4611
Endometrial Diseases
[description not available]		02.0710
Uterine Diseases
Pathological processes involving any part of the UTERUS.		02.0710
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		03.3711
Facial Dermatoses
Skin diseases involving the FACE.		01.9510
Dermatitis Seborrheica
[description not available]		02.3620
Scalp Dermatoses
Skin diseases involving the SCALP.		01.9510
Dermatitis, Seborrheic
A chronic inflammatory disease of the skin with unknown etiology. It is characterized by moderate ERYTHEMA, dry, moist, or greasy (SEBACEOUS GLAND) scaling and yellow crusted patches on various areas, especially the scalp, that exfoliate as dandruff. Seborrheic dermatitis is common in children and adolescents with HIV INFECTIONS.		02.3620
Acute Kidney Failure
[description not available]		01.9810
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		01.9810
Vulvar Diseases
Pathological processes of the VULVA.		03.3611
Hemorrhage, Uterine
[description not available]		01.9710
Hematocolpos
A blood-filled VAGINA that is obstructed.		01.9710
Uterine Hemorrhage
Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.		01.9710
Drug Overdose
Accidental or deliberate use of a medication or street drug in excess of normal dosage.		01.9710
Hypergonadotropic Hypogonadism
[description not available]		01.9710
Hypogonadism
Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).		01.9710
Urination Disorders
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.		06.9610
Leukorrhea
A clear or white discharge from the VAGINA, consisting mainly of MUCUS.		01.9610